바카라 루쥬 Bio expands Grabody-B applications to siRNA, ASO, and beyond to unlock new CNS therapeutic pipelines
바카라 루쥬 Bio is advancing its central nervous system (CNS) therapeutics business through Grabody-B, its proprietary blood-brain barrier (BBB) shuttle platform.
Initially designed to deliver antibody-based therapies across the BBB, Grabody-B is now being expanded to support nucleic acid-based modalities, including siRNA (small interfering RNA), ASO (antisense oligonucleotides), mRNA, and ribozymes. This strategic move follows a major .94 billion licensing agreement with global pharmaceutical leader GSK, marking the platform’s full-scale commercialization.
Grabody-B targets the insulin-like growth factor 1 receptor (IGF1R), which is selectively expressed in brain capillary endothelial cells. The platform leverages receptor-mediated endocytosis and transcytosis to deliver therapeutic payloads into brain tissue. Once bound to IGF1R, Grabody-B facilitates transport of drugs through endothelial vesicles across the BBB.
바카라 루쥬 Bio emphasizes that Grabody-B is modality-agnostic, designed specifically for transport rather than being limited by the structure or mechanism of the therapeutic agent. Drugs can be delivered via direct conjugation or through linkers, making the platform suit바카라 루쥬e for a wide range of CNS therapies.
Grabody-B’s receptor selection further sets it apart from conventional BBB shuttles. While transferrin receptor (TfR)-based platforms suffer from high peripheral expression, immunogenicity, and limited internalization, IGF1R offers superior BBB specificity, low peripheral expression, and higher internalization efficiency—making it a safer and more effective delivery target.
This innovation is especially critical for nucleic acid drugs, which—despite their precision in gene modulation—face challenges crossing the BBB and often accumulate in non-target organs like the liver, raising toxicity concerns. Grabody-B’s ability to transport these agents directly into the brain could improve both safety and efficacy in CNS indications.
In Alzheimer’s disease, for instance, 바카라 루쥬 Bio is employing Grabody-B to target distinct pathological epitopes of amyloid-beta (Aβ) and tau proteins, using a precision approach that accounts for cleavage, phosphorylation, and acetylation modifications.
The GSK licensing deal underscores the commercial potential of the Grabody-B platform. The agreement grants GSK full access to develop CNS therapeutics using Grabody-B, with 6 million disclosed as upfront and near-term milestone payments. Not바카라 루쥬y, the deal covers the entire platform—not just a single asset—and allows use across multiple therapeutic modalities.
Following this agreement, 바카라 루쥬 Bio has launched a comprehensive strategy to expand Grabody-B’s applications beyond antibodies. It is now actively developing and pursuing licensing and co-development partnerships for siRNA, ASO, mRNA, ribozymes, and antibody-drug conjugates (ADCs), aiming to build a diverse and scal바카라 루쥬e pipeline of CNS therapies.
A company representative stated, “Grabody-B is a flexible and expand바카라 루쥬e platform not limited to antibodies. It en바카라 루쥬es diverse licensing and partnership opportunities across the CNS therapeutic landscape.”